PHAR: מחיר למכירות Pharming

Pharming Group N.V. relies on patent protection and sales of treatments for hereditary angioedema, although the company is currently successfully reducing its dependence on a single product through new immune drugs. The company's rolling P/S visualizes this transformation, with the indicator reaching 2.40. Strategic alliances with research centers and the licensing of therapies are accelerating the global market entry of orphan drugs.

The stability of Pharming Group N.V. (PHAR) is based on the lifelong demand from insurers for high-cost drugs used to treat rare pathologies. The P/S ratio compares market capitalization to annual revenue, allowing the price-to-sales trend to determine the extent of the asset's overvaluation and assess the long-term effectiveness of monetizing patented biological developments.